by Dennis Smith | Sep 5, 2026 | News
Reported incidence of CTE found necessitates living diagnoses, not just for professional athletes, but for others where repetitive brain injuries occur. CHICAGO, IL, UNITED STATES, August 31, 2026 /EINPresswire.com/ — CereMark Pharma highlights a study published on...
by Dennis Smith | Jul 10, 2025 | News
F-18 Flornaptitril was designed to simultaneously detect tau aggregates and beta-amyloid plaques within a single PET scan WHEELING, WV – July 9, 2025 – CereMark Pharma (CereMark), a clinical-stage radiopharmaceutical company focused on the detection, diagnosis...
by Dennis Smith | Aug 1, 2024 | News
New partnership aims to improve the management of neurodegeneration associated with traumatic brain injuries from contact sports and military service CereMark Pharma, a clinical-stage radiopharmaceutical company specializing in the development of novel Positron...
by Dennis Smith | Dec 8, 2023 | News
CereMark Prepares for Pivotal Phase 3 Clinical Trial for Prediction of Cognitive Decline in Alzheimer’s Disease, CTE and Other Neurodegenerative Diseases New York, New York – June 28, 2023 CereMark Pharma LLC (“CereMark”) today announced that it has...
by Dennis Smith | Oct 7, 2023 | News
Los Angeles, California – August 2, 2022: CereMark Pharma LLC (“CereMark”) today announced that additional patents have been awarded to the University of California at Los Angeles (‘UCLA”) associated with a unique, selective imaging biomarker,...
